title

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

PVI, PeerView Institute for Medical Education

6
Followers
3
Plays
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

PVI, PeerView Institute for Medical Education

6
Followers
3
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Latest Episodes

Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

52 MIN2 weeks ago
Comments
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

Paul W. Noble, MD - A Visual Guide to Timely and Accurate Diagnosis of Idiopathic Pulmonary Fibrosis

Go online to PeerView.com/AWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in idiopathic pulmonary fibrosis (IPF) discusses key characteristics of high-resolution computed tomography (HRCT) patterns that differentiate usual interstitial pneumonia (UIP) from probable UIP, indeterminate for UIP, and non-IPF; how to decide whether a patient should undergo a lung biopsy; and implementation of new clinical guidelines for diagnosing IPF. Upon completion of this activity, participants should be better able to: Differentiate UIP from probable UIP, indeterminate for UIP, and non-IPF lung disease according to HRCT scanning patterns, Select patients who should undergo a lung biopsy or cellular analysis of broncho-alveolar lavage fluid according to evidence-based guidelines, Implement updated clinical practice guidelines for the diagnosis of IPF.

27 MINSEP 12
Comments
Paul W. Noble, MD - A Visual Guide to Timely and Accurate Diagnosis of Idiopathic Pulmonary Fibrosis

James R. Gavin III, MD, PhD - Swimming in Cloudy Water: Using the Latest Guidelines to Clear Up Clinical Confusion About T2DM Management

Go online to PeerView.com/ASM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in primary care, endocrinology, and diabetes education offer insights on providing patient-centered diabetes care and developing individualized treatment plans for patients with type 2 diabetes mellitus (T2DM). Upon completion of this activity, participants should be better able to: Reconcile recommendations offered in evidence-based clinical guidelines focusing on individualized management of type 2 diabetes mellitus (T2DM), Identify and assess patient factors and health status to appropriately individualize glycemic targets and antihyperglycemic therapy in patients with T2DM, Acknowledge the preferred role and placement of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors in current T2DM treatment algorithms.

72 MINSEP 5
Comments
James R. Gavin III, MD, PhD - Swimming in Cloudy Water: Using the Latest Guidelines to Clear Up Clinical Confusion About T2DM Management

Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare m...

33 MINAUG 17
Comments
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

Benjamin Levy, MD - Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient

Go online to PeerView.com/WED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–small cell lung cancer (NSCLC) is one of the tumor types where the novel class of cancer immunotherapies—the immune checkpoint inhibitors—has had the biggest impact and certainly become a major component of the treatment arsenal in the advanced disease setting. While the approval and availability of an increasing number and variety of immunotherapeutic agents and combinatorial options has been welcomed by clinicians and patients alike, clinical decision-making has also become quite complicated. How to identify the right candidates for immunotherapy? What biomarkers should be tested to guide candidate selection? And which agent or combination to use for individual patients? All these questions and more are explored in this engaging and entertaining educational session based on a live symposium held adjunct to the 2019 American Society of Clinical...

85 MINAUG 10
Comments
Benjamin Levy, MD - Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient

Ghassan Abou-Alfa, MD, MBA - ‘How I Think, How I Treat’—Embarking on a New Treatment Era in Hepatocellular Carcinoma: A Personal Take on Integrating Recent Evidence Into the Continuum of Care for Patients With HCC

Go online to PeerView.com/XEJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple new drug approvals and positive clinical trial outcomes have set the stage for the wider integration of novel therapeutics across the treatment spectrum of hepatocellular carcinoma (HCC). These developments have established multiple targeted and immunotherapy agents as options in advanced disease while also mapping potential future applications in intermediate stage HCC and beyond. Future care will depend on the successful integration of newer tyrosine kinase inhibitor (TKI)-based approaches with established and emerging immune checkpoint inhibitors across patient populations and lines of therapy. This PeerView “How I Think, How I Treat” activity, based on a symposium held during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, offers an inside look at how experts translate important new data and navigate the current...

105 MINAUG 8
Comments
Ghassan Abou-Alfa, MD, MBA - ‘How I Think, How I Treat’—Embarking on a New Treatment Era in Hepatocellular Carcinoma: A Personal Take on Integrating Recent Evidence Into the Continuum of Care for Patients With HCC

Michael E. Wechsler, MD - Advances in the Treatment of Uncontrolled Persistent Asthma: Expert Insights in Personalizing Patient Care

Go online to PeerView.com/PBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss recent advances in the treatment of uncontrolled persistent asthma and offer practical guidance on personalizing patient care. Upon completion of this activity, participants should be better able to: Describe the mechanisms of inflammatory pathways in uncontrolled persistent asthma and their implications for treatment, Assess patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies, Apply evidence-based guidelines and the latest clinical data when selecting treatment for patients with uncontrolled persistent asthma, Implement patient education and communication tactics in personalized treatment plans to improve patient adherence, self-management, and quality of life.

43 MINAUG 6
Comments
Michael E. Wechsler, MD - Advances in the Treatment of Uncontrolled Persistent Asthma: Expert Insights in Personalizing Patient Care

Anthony J. Mancini, MD, FAAP, FAAD - Improving the Care of Young Patients With Atopic Dermatitis: Recognizing the Differences Between Children, Adolescents, and Adults

Go online to PeerView.com/YGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert dermatologist discusses the burden and clinical manifestations of atopic dermatitis (AD) in children, adolescents, and adults and offers insight into the best practices to improve the care of young patients with this condition. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by pediatric and adolescent patients with atopic dermatitis (AD) and their caregivers, Identify the differences in clinical manifestations and differential diagnoses between children, adolescents, and adults with AD, Discuss the mechanism of action and the latest clinical data related to the efficacy and safety of currently available and emerging treatments for pediatric and adolescent AD, Employ an individualized, proactive approach to the long-term tr...

28 MINJUL 23
Comments
Anthony J. Mancini, MD, FAAP, FAAD - Improving the Care of Young Patients With Atopic Dermatitis: Recognizing the Differences Between Children, Adolescents, and Adults

Edward J. Fox, MD, PhD - Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Treatment Options and Potential Biomarkers

Go online to PeerView.com/EHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Several disease-modifying therapies (DMTs) are now approved for MS management, and a number of emerging therapies are under investigation for the treatment of this disease. In this unique PeerView Talks activity, based on a live symposium held at the 2019 CMSC Annual Meeting, leading experts engage in a live discussion of current data on available and investigational therapies for the treatment of MS, as well as how to personalize DMT selection. The faculty share their personal experiences and the “Stories Behind the Science” that connect the evidence to real-world clinical practice. Upon completion of this activity, participants will be able to: Apply available data on approved disease-modifying therapies when managing patients with multiple sclerosis, Identify recent data on the efficacy, safety, and tolerability of emerging disease-modifying thera...

49 MINJUL 18
Comments
Edward J. Fox, MD, PhD - Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Treatment Options and Potential Biomarkers

Elizabeth A. Stewart, MD - Advances in Medical Options for Uterine Fibroids and Endometriosis: Clinical Highlights From Montreal

Go online to PeerView.com/NNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gynecology/obstetrics discusses emerging data on options for the treatment of endometriosis and uterine fibroids that were presented at the 5th Congress of the Society for Endometriosis and Uterine Disorders (SEUD 2019) in Montreal in May 2019. Upon completion of this activity, participants should be better able to: Discuss the latest clinical data on current and emerging treatment options for management of endometriosis, endometriosis-associated pain, and uterine fibroids, Employ recent evidence on new and established treatment approaches for individualized therapeutic management of patients with endometriosis and uterine fibroids.

30 MINJUL 16
Comments
Elizabeth A. Stewart, MD - Advances in Medical Options for Uterine Fibroids and Endometriosis: Clinical Highlights From Montreal

Latest Episodes

Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

52 MIN2 weeks ago
Comments
Vanita R. Aroda, MD - Putting Basal Insulin Therapy to Work for Patients With Type 2 Diabetes Mellitus

Paul W. Noble, MD - A Visual Guide to Timely and Accurate Diagnosis of Idiopathic Pulmonary Fibrosis

Go online to PeerView.com/AWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in idiopathic pulmonary fibrosis (IPF) discusses key characteristics of high-resolution computed tomography (HRCT) patterns that differentiate usual interstitial pneumonia (UIP) from probable UIP, indeterminate for UIP, and non-IPF; how to decide whether a patient should undergo a lung biopsy; and implementation of new clinical guidelines for diagnosing IPF. Upon completion of this activity, participants should be better able to: Differentiate UIP from probable UIP, indeterminate for UIP, and non-IPF lung disease according to HRCT scanning patterns, Select patients who should undergo a lung biopsy or cellular analysis of broncho-alveolar lavage fluid according to evidence-based guidelines, Implement updated clinical practice guidelines for the diagnosis of IPF.

27 MINSEP 12
Comments
Paul W. Noble, MD - A Visual Guide to Timely and Accurate Diagnosis of Idiopathic Pulmonary Fibrosis

James R. Gavin III, MD, PhD - Swimming in Cloudy Water: Using the Latest Guidelines to Clear Up Clinical Confusion About T2DM Management

Go online to PeerView.com/ASM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in primary care, endocrinology, and diabetes education offer insights on providing patient-centered diabetes care and developing individualized treatment plans for patients with type 2 diabetes mellitus (T2DM). Upon completion of this activity, participants should be better able to: Reconcile recommendations offered in evidence-based clinical guidelines focusing on individualized management of type 2 diabetes mellitus (T2DM), Identify and assess patient factors and health status to appropriately individualize glycemic targets and antihyperglycemic therapy in patients with T2DM, Acknowledge the preferred role and placement of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors in current T2DM treatment algorithms.

72 MINSEP 5
Comments
James R. Gavin III, MD, PhD - Swimming in Cloudy Water: Using the Latest Guidelines to Clear Up Clinical Confusion About T2DM Management

Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare m...

33 MINAUG 17
Comments
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

Benjamin Levy, MD - Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient

Go online to PeerView.com/WED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–small cell lung cancer (NSCLC) is one of the tumor types where the novel class of cancer immunotherapies—the immune checkpoint inhibitors—has had the biggest impact and certainly become a major component of the treatment arsenal in the advanced disease setting. While the approval and availability of an increasing number and variety of immunotherapeutic agents and combinatorial options has been welcomed by clinicians and patients alike, clinical decision-making has also become quite complicated. How to identify the right candidates for immunotherapy? What biomarkers should be tested to guide candidate selection? And which agent or combination to use for individual patients? All these questions and more are explored in this engaging and entertaining educational session based on a live symposium held adjunct to the 2019 American Society of Clinical...

85 MINAUG 10
Comments
Benjamin Levy, MD - Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient

Ghassan Abou-Alfa, MD, MBA - ‘How I Think, How I Treat’—Embarking on a New Treatment Era in Hepatocellular Carcinoma: A Personal Take on Integrating Recent Evidence Into the Continuum of Care for Patients With HCC

Go online to PeerView.com/XEJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple new drug approvals and positive clinical trial outcomes have set the stage for the wider integration of novel therapeutics across the treatment spectrum of hepatocellular carcinoma (HCC). These developments have established multiple targeted and immunotherapy agents as options in advanced disease while also mapping potential future applications in intermediate stage HCC and beyond. Future care will depend on the successful integration of newer tyrosine kinase inhibitor (TKI)-based approaches with established and emerging immune checkpoint inhibitors across patient populations and lines of therapy. This PeerView “How I Think, How I Treat” activity, based on a symposium held during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, offers an inside look at how experts translate important new data and navigate the current...

105 MINAUG 8
Comments
Ghassan Abou-Alfa, MD, MBA - ‘How I Think, How I Treat’—Embarking on a New Treatment Era in Hepatocellular Carcinoma: A Personal Take on Integrating Recent Evidence Into the Continuum of Care for Patients With HCC

Michael E. Wechsler, MD - Advances in the Treatment of Uncontrolled Persistent Asthma: Expert Insights in Personalizing Patient Care

Go online to PeerView.com/PBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss recent advances in the treatment of uncontrolled persistent asthma and offer practical guidance on personalizing patient care. Upon completion of this activity, participants should be better able to: Describe the mechanisms of inflammatory pathways in uncontrolled persistent asthma and their implications for treatment, Assess patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies, Apply evidence-based guidelines and the latest clinical data when selecting treatment for patients with uncontrolled persistent asthma, Implement patient education and communication tactics in personalized treatment plans to improve patient adherence, self-management, and quality of life.

43 MINAUG 6
Comments
Michael E. Wechsler, MD - Advances in the Treatment of Uncontrolled Persistent Asthma: Expert Insights in Personalizing Patient Care

Anthony J. Mancini, MD, FAAP, FAAD - Improving the Care of Young Patients With Atopic Dermatitis: Recognizing the Differences Between Children, Adolescents, and Adults

Go online to PeerView.com/YGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert dermatologist discusses the burden and clinical manifestations of atopic dermatitis (AD) in children, adolescents, and adults and offers insight into the best practices to improve the care of young patients with this condition. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by pediatric and adolescent patients with atopic dermatitis (AD) and their caregivers, Identify the differences in clinical manifestations and differential diagnoses between children, adolescents, and adults with AD, Discuss the mechanism of action and the latest clinical data related to the efficacy and safety of currently available and emerging treatments for pediatric and adolescent AD, Employ an individualized, proactive approach to the long-term tr...

28 MINJUL 23
Comments
Anthony J. Mancini, MD, FAAP, FAAD - Improving the Care of Young Patients With Atopic Dermatitis: Recognizing the Differences Between Children, Adolescents, and Adults

Edward J. Fox, MD, PhD - Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Treatment Options and Potential Biomarkers

Go online to PeerView.com/EHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Several disease-modifying therapies (DMTs) are now approved for MS management, and a number of emerging therapies are under investigation for the treatment of this disease. In this unique PeerView Talks activity, based on a live symposium held at the 2019 CMSC Annual Meeting, leading experts engage in a live discussion of current data on available and investigational therapies for the treatment of MS, as well as how to personalize DMT selection. The faculty share their personal experiences and the “Stories Behind the Science” that connect the evidence to real-world clinical practice. Upon completion of this activity, participants will be able to: Apply available data on approved disease-modifying therapies when managing patients with multiple sclerosis, Identify recent data on the efficacy, safety, and tolerability of emerging disease-modifying thera...

49 MINJUL 18
Comments
Edward J. Fox, MD, PhD - Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Treatment Options and Potential Biomarkers

Elizabeth A. Stewart, MD - Advances in Medical Options for Uterine Fibroids and Endometriosis: Clinical Highlights From Montreal

Go online to PeerView.com/NNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gynecology/obstetrics discusses emerging data on options for the treatment of endometriosis and uterine fibroids that were presented at the 5th Congress of the Society for Endometriosis and Uterine Disorders (SEUD 2019) in Montreal in May 2019. Upon completion of this activity, participants should be better able to: Discuss the latest clinical data on current and emerging treatment options for management of endometriosis, endometriosis-associated pain, and uterine fibroids, Employ recent evidence on new and established treatment approaches for individualized therapeutic management of patients with endometriosis and uterine fibroids.

30 MINJUL 16
Comments
Elizabeth A. Stewart, MD - Advances in Medical Options for Uterine Fibroids and Endometriosis: Clinical Highlights From Montreal